The good news keeps flowing at Isis (ISIS +0.2%) this week (see I, II) as the FDA grants...

|By:, SA News Editor

The good news keeps flowing at Isis (ISIS +0.2%) this week (see I, II) as the FDA grants fast-track designation for the company's ISIS-TTR drug for treating familial amyloid polyneuropathy (FAP), a rare genetic disease that is a form of transthyretin amyloidosis and leads to the loss of nerve function and wasting. Isis is developing ISIS-TTR with GSK (GSK -0.4%) to treat transthyretin amyloidosis and the companies hope to start Phase 2/3 trials this month.